171 related articles for article (PubMed ID: 38387940)
21. SPLENECTOMY FOR MARKED SPLENOMEGALY DUE TO EXTRAMEDULLARY HEMATOPOIESIS.
SNYDER H
Med Rec Ann; 1964 Jan; 57():277-8. PubMed ID: 14115110
[No Abstract] [Full Text] [Related]
22. The EMT transcription factor Zeb2 controls adult murine hematopoietic differentiation by regulating cytokine signaling.
Li J; Riedt T; Goossens S; Carrillo García C; Szczepanski S; Brandes M; Pieters T; Dobrosch L; Gütgemann I; Farla N; Radaelli E; Hulpiau P; Mallela N; Fröhlich H; La Starza R; Matteucci C; Chen T; Brossart P; Mecucci C; Huylebroeck D; Haigh JJ; Janzen V
Blood; 2017 Jan; 129(4):460-472. PubMed ID: 27683414
[TBL] [Abstract][Full Text] [Related]
23. JAK inhibitors in the treatment of myelofibrosis.
Levavi H; Hoffman R; Marcellino BK
Clin Adv Hematol Oncol; 2022 Jul; 20(7):456-467. PubMed ID: 35802878
[TBL] [Abstract][Full Text] [Related]
24. CXCR4-independent rescue of the myeloproliferative defect of the Gata1low myelofibrosis mouse model by Aplidin.
Verrucci M; Pancrazzi A; Aracil M; Martelli F; Guglielmelli P; Zingariello M; Ghinassi B; D'Amore E; Jimeno J; Vannucchi AM; Migliaccio AR
J Cell Physiol; 2010 Nov; 225(2):490-9. PubMed ID: 20458749
[TBL] [Abstract][Full Text] [Related]
25. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
[TBL] [Abstract][Full Text] [Related]
26. State-of-the-Art Review on Myelofibrosis Therapies.
Wang F; Qiu T; Wang H; Yang Q
Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e350-e362. PubMed ID: 34903489
[TBL] [Abstract][Full Text] [Related]
27. Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors.
Randhawa J; Ostojic A; Vrhovac R; Atallah E; Verstovsek S
J Hematol Oncol; 2012 Aug; 5():43. PubMed ID: 22852872
[TBL] [Abstract][Full Text] [Related]
28. Assessment of sites of marrow and extramedullary hematopoiesis by hybrid imaging in primary myelofibrosis patients.
Ojeda-Uribe M; Morel O; Ungureanu C; Desterke C; Le Bousse-Kerdilès MC; Boulahdour H
Cancer Med; 2016 Sep; 5(9):2378-84. PubMed ID: 27518041
[TBL] [Abstract][Full Text] [Related]
29. Treatment of Myelofibrosis: A Moving Target.
Cerquozzi S; Farhadfar N; Tefferi A
Cancer J; 2016; 22(1):51-61. PubMed ID: 26841017
[TBL] [Abstract][Full Text] [Related]
30. [Recent advances in the treatment of myelofibrosis].
Takenaka K
Rinsho Ketsueki; 2020; 61(9):1195-1204. PubMed ID: 33162516
[TBL] [Abstract][Full Text] [Related]
31. CDK6 Is a Therapeutic Target in Myelofibrosis.
Dutta A; Nath D; Yang Y; Le BT; Mohi G
Cancer Res; 2021 Aug; 81(16):4332-4345. PubMed ID: 34145036
[TBL] [Abstract][Full Text] [Related]
32. Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan.
Chen YY; Huang CE; Lee KD; Chen CC
Hematology; 2016 Jan; 21(1):3-9. PubMed ID: 26214121
[TBL] [Abstract][Full Text] [Related]
33. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2016 Dec; 91(12):1262-1271. PubMed ID: 27870387
[TBL] [Abstract][Full Text] [Related]
34. Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib.
Saha C; Harrison C
Expert Rev Hematol; 2022 Jul; 15(7):583-595. PubMed ID: 35787092
[TBL] [Abstract][Full Text] [Related]
35. Extramedullary hematopoiesis in an inguinal lymph node: an unusual presentation of primary myelofibrosis.
Yaqoob N; Mansoor N; Naveed H; Jamal S
World J Surg Oncol; 2022 Jun; 20(1):186. PubMed ID: 35676715
[TBL] [Abstract][Full Text] [Related]
36. Splenic pooling and loss of VCAM-1 causes an engraftment defect in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation.
Hart C; Klatt S; Barop J; Müller G; Schelker R; Holler E; Huber E; Herr W; Grassinger J
Haematologica; 2016 Nov; 101(11):1407-1416. PubMed ID: 27662011
[TBL] [Abstract][Full Text] [Related]
37. Massive splenomegaly and extramedullary hematopoiesis in chronic idiopathic myelofibrosis.
Montague N; De La Ossa M
Blood; 2010 Oct; 116(14):2410. PubMed ID: 20949696
[No Abstract] [Full Text] [Related]
38. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.
Talpaz M; Kiladjian JJ
Leukemia; 2021 Jan; 35(1):1-17. PubMed ID: 32647323
[TBL] [Abstract][Full Text] [Related]
39. Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies.
Zahr AA; Salama ME; Carreau N; Tremblay D; Verstovsek S; Mesa R; Hoffman R; Mascarenhas J
Haematologica; 2016 Jun; 101(6):660-71. PubMed ID: 27252511
[TBL] [Abstract][Full Text] [Related]
40. Captopril mitigates splenomegaly and myelofibrosis in the Gata1
Corey SJ; Jha J; McCart EA; Rittase WB; George J; Mattapallil JJ; Mehta H; Ognoon M; Bylicky MA; Summers TA; Day RM
J Cell Mol Med; 2018 Sep; 22(9):4274-4282. PubMed ID: 29971909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
